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Abstract: Cholera toxin subunit B (CTB) is the nontoxic portion of cholera toxin. Its affinity 
to the monosialotetrahexosylganglioside (GM1) that is broadly distributed in a variety of cell 
types including epithelial cells of the gut and antigen presenting cells, macrophages, 
dendritic cells, and B cells, allows its optimal access to the immune system. CTB can easily 
be expressed on its own in a variety of organisms, and several approaches can be used to 
couple it to antigens, either by genetic fusion or by chemical manipulation, leading to 
strongly enhanced immune responses to the antigens. In autoimmune diseases, CTB has the 
capacity to evoke regulatory responses and to thereby dampen autoimmune responses, in 
several but not all animal models. It remains to be seen whether the latter approach translates 
to success in the clinic, however, the versatility of CTB to manipulate immune responses in 
either direction makes this protein a promising adjuvant for vaccine development.  
Keywords: Cholera toxin subunit B (CTB); adjuvant; expression; oral tolerance;  
immunity; autoimmunity 
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1. Introduction 
Cholera toxin is the soluble toxin secreted by the Gram negative bacteria Vibrio cholerae. The toxin 
is composed of two proteins, the subunit A (CTA) that exists as a monomer in the complex, and the 
subunit B (CTB) that forms a pentamer. The dual protein nature of cholera toxin was initially recognized 
by Lönnroth and Holmgren in 1973 [1], and structural studies of the closely related heat-labile 
enterotoxin from Escherichia coli [2] and subsequently of cholera toxin and CTB confirmed these initial 
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findings [3,4]. CTB forms a ring-like structure composed of five CTB monomers. Each monomer 
interacts with two neighboring molecules through hydrogen bonds and salt bridges without being 
covalently linked to each other. The center of this pentameric formation adopts a tunnel-like structure, 
the wall of which is formed by five alpha helices (2), each one belonging to a different monomer. CTA 
has a globular structure with a protruding C-terminal alpha helical extension. This extension inserts into 
the tunnel formed by the CTB pentamer that accepts only a single CTA molecule, leading the final AB5 
hexameric structure of cholera toxin [5]. CTA is generated as a single protein chain, however, due to a 
proteolytic cleavage CTA is split into two subunits, CTA1 and CTA2, that remain combined in the 
hexamer until the complex has entered the host cells and reached the endoplasmatic reticulum. CTA1 
corresponds to the globular portion of CTA, while CTA2 forms the protruding alpha helix that inserts 
into the tunnel by the pentamer. The toxic portion of cholera toxin is CTA, and more specifically, CTA1. 
After cell entry, CTA1 eventually reaches the endoplasmatic reticulum and next the cytosol [6] where it 
interacts with adenylate cyclase, leading to its activation. Adenylate cyclase catalyzes the conversion of 
ATP to 3',5'-cyclic AMP which in turn is responsible for the activation of cystic fibrosis transmembrane 
conductance regulator (CFTR) channel [7]. This leads to a salt imbalance of the epithelial cells in the 
gut characteristic for enterotoxic poisoning. Epithelial cells under these conditions increase the extrusion 
of chloride ions, and simultaneously the uptake of sodium is prevented. This leads to a fatal loss of water 
by the intestine. 
The cellular uptake of cholera toxin is regulated by the recognition of its receptor, the 
monosialotetrahexosylganglioside (GM1a, Gal3GalNAc4(Neu5Ac3)Gal4GlcCer; for nomenclature 
and structure please view [8]). The identity of GM1 as a receptor for cholera toxin was elaborated by 
Holmgren and colleagues in 1973 [9]. CTB interacts with GM1 through its pentasaccharide moiety.  
Each CTB monomer interacts primarily with one pentasaccharide, however, each pentasaccharide also 
extends its contacts to an adjacent CTB molecule. This explains why CTB needs to adopt a pentameric 
formation to gain maximal function. The optimal sugar binding of two B subunits is only then combined 
with the additional avidity obtained by simultaneous interaction with more than one GM1 ganglioside. 
The pentasaccharide-CTB interaction further enhances the interaction between B subunits within the 
pentamer [10].  
The fact that CTB is non-toxic has made this molecule an excellent delivery vehicle, given the cellular 
distribution of its receptor. GM1 is found on a broad variety of cell types including neurons [11]. 
Pertinent to this review is the presence of this ganglioside on the surface of the epithelial cells in the gut 
as this is a crucial entry point into the body when using CTB in oral vaccine formulations, and on antigen 
presenting cells. Apart from macrophages and dendritic cells [12], GM1 is also expressed by B cells in 
which upon CTB binding expression of MHC class II is increased [13]. This vastly increases antigen 
presentation of CTB and molecules coupled to it in the organism. In a homeostatic setting, typically only 
a very limited number of Ag-specific B cells exists in the total B cell repertoire that will efficiently 
capture Ag via the B cell receptor (BCR) recognizing the Ag and guide it towards the MHC class II 
loading compartment. Ag capture via CTB and GM1 bypasses this loophole, which therefore potentially 
converts the entire B cell compartment into potential antigen presenters, in addition to macrophages and 
dendritic cells. 
  
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2. CTB Expression in Bacteria and Yeast 
The CTB monomer is composed of 124 amino acids including the leader peptide of 21 residues. The 
mature form contains 103 amino acids and has a molecular weight of 11.6 KD [14]. CTA and CTB, after 
synthesis in the cytoplasm, are guided to the periplasm. Here, CTB assembles to form the pentamer 
which is either secreted separately or may bind to CTA to form the holotoxin AB5 which next is  
secreted [15]. Its relatively small size and its close similarity to the enterotoxin from E. coli facilitates 
its recombinant expression in this host. In E. coli, recombinant overexpression of CTB is generally 
carried out omitting the leader peptide in the expression constructs, leading to the formation of inclusion 
bodies. However, the protein can be solubilized in urea and readily refolds under proper conditions [16]. 
The protein is well expressed, with typical yields of purified protein exceeding 100 mg/L of bacterial 
culture volume in our laboratory. Proper refolding and formation of the pentameric structure needs to be 
verified e.g., by size exclusion chromatography and by SDS-PAGE under native conditions in which the 
pentamer maintains its conformation [17]. The functionality of the pentamer can be tested by its binding 
capacity to immobilized D-galactose [18]. CTB has further been expressed in Lactobacillus and its 
immunogenicity verified by challenging mice intranasally with purified CTB [19]. 
Miyata and colleagues reported the expression of CTB in methylotrophic yeast (Pichia pastoris) [20] 
(Table 1). Compared to bacterial expression, the expression in yeast has the advantage of being 
conveniently similar to bacterial culture, yet without the generation of endotoxins. Other advantages of 
yeast, to take into consideration when fusing CTB to proteins that need proper folding, are the disulfide 
bond formation and the glycosylation. Approximately 50 mg/L of culture can be obtained in this system. 
Another methylotrophic yeast species, Hansenula polymorpha, has been used to express CTB fused  
N-terminally to short epitopes of the foot-and-mouth disease virus. Up to 100 mg of the fusion protein 
was obtained per liter of culture volume in this system [21].  
Table1.Expression systems of CTB and CTBfusion proteins.  
Expression System CTB Fused to Reported Yields Ref.
E. coli BL21 Fimbria 2 (Bortedellapertussis), Cterm. Not specified [22] 
E. coli BL21  
Adhesin from Streptococcus, fused to 
CTA2, CTB coexpressed but unfused 
3.5 mg/L of culture [23] 
E. coli KS476 
Albumin binding region (BB) of 
Streptococcus protein G Nterminal,  
Cterminal and both, N- and Cterminal 
6–12 mg/L of culture [24] 
E. coli BL21 (DE3) 
Cedar pollen Ag cry j 1 and cry j 2,  
Cterminal 
120 mg/L culture volume [25] 
Lactobacillus casei 
Lactobacillus reuteri 
Hexahistidine tag or unfused 
0.05 mg/L unfused, 1 mg/L 
when fused to histidine tag 
[19] 
Lactobacillus casei 
YVAD tetrapeptide (caspase1 inhibitor), 
Cterminal 
1 mg/L culture volume [26] 
Yeast (Pichia pastoris) 
CTB stabilized by fusion to five stranded 
helical coiledcoil domain of cartilage 
oligomeric matrix protein(COMP)  
Not specified  [27] 
Silkworm (Bombyx mori) amyloid peptide(A42), C-term 0.5 μg/g silkworm pupae  [28] 
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Table 1. Cont. 
Expression System CTB Fused to Reported Yields Ref.
Silkworm (Bombyx mori)  InsulinGFP 
0.58 mg/mL of hemolymph, 
0.23 mg/larva 
[29] 
Tobacco  
(Nicotiana benthamiana) 
unfused >1 g/kg of fresh leaves [30] 
Tobacco  
(Nicotiana benthamiana)  
HIV membrane proximal (ectodomain) 
region of gp41, C-term 
1–2 mg purified protein/kg 
of fresh leaves 
[31] 
Tobacco 
(Nicotianatabacum var. 
Petit havana)  
unfused 
4.1% of total soluble leaf 
protein 
[32] 
Tobacco  
(Nicotiana tabacum var. 
Petit havana), chloroplast 
Mycobacterium Ag ESAT6 (6 kDa early 
secretory antigenic target) and Mtb72F (a 
fusion polyprotein from two TB antigens, 
Mtb32 and Mtb39) 
0.95 mg/g fresh leaf  
(CTB-ESAT6), 1.1% of 
total soluble protein  
(CTBMtb72F) 
[33] 
Tobacco  
(Nicotiana tabacum)  
Nterminal fused to p201 epitope  
from ApoB100 and CETP 461–476,  
Cterminal 
10 mg/kg of fresh plant leaf [34] 
Tobacco MBP,Cterminal 2% of total leaf protein  [35] 
Rice (Oryza sativa japonica, 
Nipponbare) 
Unfused, Asn to Gln substitution at 4th 
glycosylation position 
2.3 mg/g of seed CTB 
unglycosylated 
[36] 
Apo: Apolipoprotein;CETP: cholesterylestertransferprotein;CETP:cholesterylestertransfer protein; 
MBP: myelinbasicprotein. 
3. CTB Expression in Plants  
CTB has been expressed successfully in various plant systems, for example in tobacco (Nicotiana 
benthamiana), where the protein, unlike the bacterially expressed form, gets glycosylated, presumably 
at position Asn25, which does not affect the pentamer formation [31]. Its binding capacity to GM1 was 
found to be decreased approximately five-fold in an ELISA assay in comparison to bacterially expressed 
CTB, however, in a hemagglutination assay using GM1 coated sheep red blood cells both proteins were 
indistinguishable, probably as this assay is less sensitive [31]. In this particular case, CTB was fused to 
the membrane proximal (ectodomain) region of gp41 (MPR649–684), and made up 0.14% of the total 
soluble protein, or approximately 20 mg per kg of fresh leaf material. The protein was immunogenic, 
and although no direct side-by-side comparison with the bacterial version of the same construct in the 
study was carried out, the authors noted that three doses were sufficient to raise a vaginal IgA towards 
the protein, something they did not achieve in previous studies using bacterially expressed protein [37]. 
The authors speculated that this might be due to the interaction between the high mannose glycans of 
the glycosylated CTB and the mannose receptors on the surface of APCs. The same group reanalyzed in 
a subsequent study unfused glycosylated CTB versus bacterial CTB and found that both proteins bound 
almost equally well to GM1 in a low nanomolar range [38]. In that case a side-by-side comparison of 
immunogenicity between both proteins was conducted. No statistically significant differences were 
detected in fecal IgA, serum IgG or the composition of IgG subtypes. Preventing the N-terminal 
glycosylation led to necrosis in the plant tissue and a reduction in production yields. N-glycosylation 
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reduced ER stress and improved proper folding of the protein [38]. CTB expression in this system fused 
to epitopes of proteins relevant to arteriosclerosis, namely the apolipoprotein ApoB100 that has been 
implicated in inflammation and depositions, leading to chronic inflammation of the arteries, as well as a 
second protein implicated in this process, the cholesteryl ester transfer protein (CETP), has been 
achieved. The fusion proteins were capable to generate Abs in vivo against the epitopes of interest in 
BALB/c mice [34]. Thus, the integrity of the epitopes was maintained in the plant. Another group, 
however, reported that elimination of N-glycosylation of CTB, expressed by its own, led to an improved 
expression yield in Nicotiana. The authors showed that this nonglycosylated CTB had similar properties 
compared to bacterial CTB, and when orally administered to mice could generate protective anti-toxin 
Abs [30]. 
A different approach of subcellular localization in Nicotiana, i.e., the expression in chloroplasts, has 
been chosen by Lakshmi et al. [33]. This was achieved by cloning CTB fused to Mycobacterium 
tuberculosis derived epitopes, i.e., the 6 KD early secretory antigenic target (ESAT-6) and Mtb72F  
(a protein resulting from the fusion of two TB antigens, Mtb32 and Mtb39), downstream of the psbA 
promoter that normally regulates expression of the protein D1, a component of the Photosystem II.  
CTB in chloroplasts formed functional GM1 binding pentamers, however, whether or not the vaccine 
lead to a protective immune response was not investigated in this study. Chloroplast expression of CTB 
has also been achieved by the generation of targeting vectors, leading to insertion of CTB coding DNA 
into chloroplast DNA. The expressed protein was found to make up 4% of the total plant protein, and 
functional pentamers accumulated in the chloroplasts. The plant-expressed pentamers bound to GM1 in 
an ELISA format as did bacterially expressed CTB; however, since total plant extract was used rather than 
purified CTB, no detailed comparative conclusions on the GM1 binding capacity could be drawn [32]. 
Expression of CTB has also been successful in rice to serve as cholera vaccine [39–41] that was 
protective in mice and macaques when administered orally [36,41]. The intent to reduce by RNAi the 
expression of rice allergens that could lead to adverse effects in humans had the beneficial effect that in 
these plants CTB expression was improved several-fold. This was accompanied with a change of 
intracellular localization of CTB. Whereas in plants without RNAi suppression CTB was detected in the 
cytoplasm and in protein bodies II, in the presence of RNAi suppression CTB was found in the 
cytoplasm, the plasma membrane and the cell wall [42]. 
4. CTB Expression in Silk Worms 
CTB fusion proteins have further been successfully produced in silkworms. In one study, CTB fused 
to the 42 amino acid isoform of the amyloid- peptide A42 in this system was successfully used in a 
mouse model for Alzheimer’s disease to reduce A deposition in the brain [28]. A fusion product of 
CTB and insulin in the same system has been claimed to reduce insulitis and diabetes onset when 
administered orally in a relevant type 1 diabetes model, the nonobese diabetic (NOD) mouse [43,44]. 
The same results were obtained with a GFP-tagged CTB-insulin fusion protein (CTB-INS-GFP) 
generated to analyze binding of the protein to the intestinal wall [29]. 
  
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5. Formulation of CTB as Adjuvant 
When using CTB as adjuvant to direct the protein of interest to the desired cells, several approaches 
can be taken (Tables 1 and 2). A common form is to fuse CTB recombinantly to the antigen of interest. 
A systemic analysis has evaluated the C-terminal versus the N-terminal fusion to CTB [24]. For this 
study, a 25 KD fusion partner, the serum albumin binding region (BB) of protein G from Streptococcus, 
was fused either N-terminally, C-terminally, or C and N-terminally simultaneously. While CTB as fusion 
partner was found to be quite permissive, i.e., all three proteins were expressed and formed pentamers, 
of the three fusion proteins, the C-terminal fusion led to the best pentamer formation and showed highest 
affinity to GM1. In case that either CTB does not fold properly, the pentamer does not form or the 
binding capacity to GM1 is affected, a different approach can be used by replacing CTA1 with the Ag 
and fusing it N-terminally to CTA2; if this construct is coexpressed together with wild type CTB [23], 
a CTB pentamer will form, into which CTA2 will insert via the tunnel formed by CTB, leaving the Ag 
protruding out of the ring structure. This construct leaves the CTB moiety without any modification, and 
GM1 binding by the pentamer is thus optimal. However, this approach also decreases the molecular ratio 
of Ag to the CTB pentamer from 5:1 to 1:1, which would need to be taken into account when comparing 
vaccine dose of different fusion proteins, unless several Ag molecules or peptide epitopes are fused to 
each other in combination with CTA2. If the stability of CTB is an issue, e.g., when fused to larger 
proteins, the CTB pentamer can be further stabilized by engineering either cysteine bridges that 
interconnect the monomer between each other [45], or by the introduction of coiled coils at the C-terminus 
of recombinant CTB [46], leading to heat-stable formation of the pentamer in both cases.  
Instead of recombinant fusion, CTB may be coadministered with Ag without being physically linked 
to each other, or it may be chemically coupled to the Ag. Furthermore, the protein can either be expressed 
and purified, or in the case of expression in plants, the purification may be omitted by generating an 
edible plant vaccine. Another way to circumvent protein purification is to include CTB into DNA vaccines. 
Chemical coupling has the advantage that CTB on its own normally expresses very well while its 
expression with a fusion partner might decrease expression levels. In our hands for example, expression 
levels of CTB in E. coli were very high, reaching more than 100 mg of purified CTB per liter of culture 
volume. Fusion of even small peptides to the C-terminus led to decreased expression levels depending 
on the peptide, cutting down the total yield to a third in some cases (unpublished observation). Chemical 
coupling can be convenient when the response to synthetically produced peptides or commercially 
available proteins are to be analyzed. Chemical coupling can be achieved randomly by targeting  
amino groups [47]. A different approach to link antigen to CTB was used recently by Miyata and 
colleagues [20]. The group expressed CTB in yeast and coupled the antigen of interest, merozoite surface 
protein-1 from Plasmodium yoelii, via N-linked oligosaccharides of CTB. The authors reported that this 
conjugation led to a higher protection against a challenge with Plasmodium in mice compared to 
conjugation of the same protein to the CTB core protein. 
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Table 2. Adjuvant effect of CTB. 
Antigen?  Fused to CTB?  (Animal) ?Model,? Pathogen, ?Route?  Analyzed ?Response?  Ref.? 
OVA?  conjugated?  DO11.10?OVA?TCR? transgenic? mice, ?i.g.?  
Induction ?of? CD25 + ?Treg? > ?2-fold? compared? to? OVA 
only,?Treg ?have ?suppressor ?function?  
[47]?  
OVA?  unfused? or? conjugated?  
DC? in? vitro ?exposed ?to ?OVA, ?CFA? +? 
CTB, ?OVA ?coupled ?to ?CTB and? transfer? 
to? BALB/c? mice?, boost? with ?OVA? +? CFA 
IgG titers >3?fold increase, upregulation of CD80 andCD86 
(CTB ?coupled? to ?OVA ?vs. ?CTB? + ?OVA ?or? OVA? only)? 
Upregulation ?of? IFN-γ? (CTB ?coupled ?to ?OVA vs. ?OVA)?  
[48]?  
OVA?  unfused?  
BALB/c ?mouse,? asthma ?OVA? aerosol ?
airway? model 
Suppression? of? airway? eosinophilia,? Th2 ?cytokine? synthesis,? 
bronchial? hyperreactivity,? Treg? induction? >?10?fold ?anti?
OVA ?IgA? increment? in ?lung? (OVA + CTB? vs.?OVA ?only)?  
[49]?  
OVA? myelin?
oligodendrocyte?
glycoprotein? peptide ?
(MOG 35–55)?  
conjugated?  
BALB/c, ?C57BL/6,? induced ?EAE? ex? vivo? 
incubation ?of? B? cells ?with? Ag? + ?CTB ?and? 
in ?vivo ?transfer?  
IL?10? production? by? B cells; ?>?50?fold ?increase ?of  
anti?OVA ?Foxp3 + ?Treg;? prevention? of ?EAE? induction?  
[50]?  
OVA?  
C?terminal, ?DNA? vaccine?
(pSV?OVA?CTB)? combined ?
with? recombinant? Tiantan? 
vaccinia ?(rTTV?OVA-CTB)?  
C57BL/6? mouse, ?oral, ?i.n. ?prime? with ?
pSV?OVA-CTB,? i.m. boost? with ? 
rTTV?OVA?CTB  
Triplication? of ?Ag-specific ?T ?cells? compared ?to? same? 
DNA? vaccines? lacking CTB?  
[51]?  
HIV?rgp160?  
unfused, ?combined ?with? 
proteasomes ?or? emulsomes?  
BALB/c? mouse,? oral/i.n.?  
Serum IgA,? 20?fold? increase ?(proteasome ?vs.? proteasome? 
+? CTB)?, intestinal? IgA, ?60?fold? increase ?(proteasome ?vs.? 
proteasome? + ?CTB)?  
[52]?  
HIV ?gp120 ?coding? 
DNA? (DNA?EnvB) ?
+ ?MVA-EnvB? (boost)? 
unfused, ?+/ IL?12 ?coding? 
DNA?  
BALB/c ?mouse,? i.n.?  
Ag?specific ?T? cell? response? duplicated? (DNA?EnvB ?+?  
IL?12? +? CTB? vs.? DNA?EnvB)?  
[53]?  
Envelope ?GP1455m? 
HIV?  
unfused?  BALB/c? mouse,? i.m. IgG ?titers 10?fold? increased? (DNA ?+? CTB ?vs. ?DNA? only)?  [54]?  
HIV? membrane ?
proximal? (ectodomain)? 
region? of? gp41?  
C?terminal?  
BALB/c ?mouse. ?i.n., ?liposome? 
conjugated? + ?CT, ?i.p.? boost? without? CT?  
Serum ?IgG ?and ?vaginal? IgA ?detected, ?titer ?increased ? 
100?fold,? however,? not ?all? mice ?responding?  
[31]?  
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Table 2. Cont. 
Antigen Fused to CTB?  (Animal) ?Model,? Pathogen,? Route?  Analyzed ?Response?  Ref.?  
Hemagglutinin? fused ?
to? major ?
immunodominant ?
region ?(MIR) ?of ?
Hepatitis ?B ?virus ?core?
protein ?(HBc)? 
unfused, ?mixed ?with ?0.2%?CT? 
BALB/c? mouse,? in? vivo ?challenge? with?
Influenza,? i.n.?  
50% ?increase ?of? survival? at ?low? Ag? dose  
?(HA? +? CTB? vs. ?HA)? 
[55]?  
Adhesin ?from?
Streptococcus? 
(AgI/II)? 
fused? to ?CTA2, ?CTB?
Coexpressed ?but? unfused? 
BALB/c? mouse,? i.n.? or ?orally,? +/ CT,?  
/+? Al(OH)3?, no ?comparison ?to ?AgI/II ?
only 
IgG? and? IgA ?titers ?analyzed? CT ?and? AL(OH)3 ?increase? 
IgG ?and? IgA ?titers ?2–10? fold? when ?added ?to? fusion? 
construct? CT? augments ?serum? IgA ?titers? over ?2?fold? 
compared ?to? Al(OH)3? 
[23]?  
Fimbria?2?  
(Bortedella pertussis)? 
C?terminal?  
BALB/c ?mouse? respiratory? model,? 
Bortedella ?pertussis? i.p.? or ?i.n.? 
IgG ?in ?serum? close ?to? ducplicated ?after ?intranasal ?
vaccination,? IgG ?in? bronchoalveolar? fluid ?4?fold ?increased? 
(CTB?Fim2 ?vs. ?recombinant? Fim2)? 
[22]?  
Urease? fragments,? 5?T? 
and ?B ?cell? epitopes? 
(Heliobacter?py lori)?  
C?terminal,? transformed? 
Lactococcus? lactis?  
BALB/c, ?oral? immunization ?with ?live? 
Lactococcus?  
>?100?fold ?reduction? of? gastric? colonization? by H.? pylori?  [56]?  
CTB?  N/A?  Monocyte?derived? DC?  
CTB? interfers ?with? LPS-induced ?maturation? IL?12 ?
production ?reduced? by? >50%? CTB?treated ?DC ?reduce? 
IFN-γ? by? T?cells ?(>60%), ?IL?10? and? TGF-? unchanged?  
[57]?  
CTB?  N/A?  
suckling? mouse? model,? females?
immunized ?i.p., ?s.c. ?or ?i.n.,? pups?
challenged ?with? V.? cholerae?  
60%–100%? survival? of? offsprings from immunized? vs. ?
PBS? treated females 
[58]?  
CTB?  
unfused,? Asn ?to ?Gln?
substitution? at? 4th?
glycosylation? position?  
Macaque,? oral? BALB/c? mouse, ?oral?  
Mice: ?protection? against? diarrhea,? detection ?of ?serum? IgG, ?
fecal ?IgA?;  
Macaques: ?detection of serum IgG,? no fecal? IgA?  
[36]?  
Naf1?  
(Naegleria?fowleri)?  
unfused?  
BALB/c? mouse, ?amoebic? 
meningoencephalitis, ?i.n.?  
60% ?vs. ?0% Survival? (Naf1? +? CTB ?vs.? Naf1)? of? mice?
infected ?with? N.f.?  
[59]?  
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Table 2. Cont. 
Antigen?  Fused ?to? CTB?  (Animal) ?Model,? Pathogen,? Route?  Analyzed ?Response?  Ref.?  
Plasmodium? vivax?
ookinete ?surface?
protein (P vs. 25)? 
conjugated? or? mixed with?
CTB? ? 
BALB/c ?mouse, ?i.n.? or ?i.p.,? +/ ?IFA? 
10?fold? increase? of? IgG? sera titers ?using ?conjugated ?
protein? vs. ?P vs. 25 ?only? or ?P vs. 25 ?+ ?CTB? 
[60]?  
Plasmodium yoelii?
Merozoite? surface 
protein?1?(MSP1)?  
C-terminal? region? 
conjugated? to? CTB ?or mixed? 
with ?CT? or ?IFA? 
C57BL/6? mouse, i.n., ?s.c., immunized? 
mice? challenged? with ?lethal ?dose ?of ? 
P.? yoelii? 
>?10?fold ?increase? of ?IgG? sera ?titer? (conjugated? vs.? MSP1? 
only),? conjugated? MSP + CT ?or ?IFA ?leads? to ?further? 5–10 
fold? titer? increase? compared? to ?conjugated ?only,? full? 
protection? against ?parasite ?only? when ?mixing? conjugated? 
MSP with ?CT ?or ?IFA? (survival ?10/10 ?vs. ?0–2/10)? 
[20]?  
Human? Pro-insulin?  C?terminal?  
monocyte?derived? dendritic ?cells?
(MoDCs), ?human,? in? vitro?  
Tolerogenic? effect on? DCs, ?indoleamine? 2,?3-dioxygenase ?
upregulation?  
[61]?  
Insulin?  C?terminal? +/ GFP?  NOD ?mouse,? T1D ?model,? oral? feeding?  50% ?reduction ?of? T1D? incidence?  [29]?  
MBP?  C?terminal?  3× TgAD ?mice ?(Alzheimer disease),? oral?  
Reduction? of ?amyloid? loads ?by? 70% ?in? hippocampus ?and? 
cortex ?brain ?region?  
[35]?  
Human ?GAD55?  
C?terminal,? recombinant? 
vaccinia? virus?  
NOD ?mouse,? i.p.,? +/? CFA?  
Diabetes? reduction? between? 50? and? 20%? compared? to? 
same? vaccine? w/o? CFA?  
[62]?  
amyloid? peptide? 
(A42)?  
C?terminal?  
B6C3?Tg (APPswe, ?PSEN1dE9)?
transgenic? mice? (Alzheimer),? oral?  
Ab ?titers? augmented? but ?n.s. ?(A42? vs. ?CTB?A42)? 
Learning ?improved ?but? n.s. ?(A42 ?vs. ?CTB?A42)?  
[28]?  
MVA: modified vaccinia Ancara; gp: glycoprotein; IFA: incomplete Freund’s adjuvant; CT: cholera toxin; i.n.: intranasal; i.p.: interperitoneal; s.c.: subcutaneous; MBP: 
myelin basic protein; GAD: glutamic acid decarboxylase; CFA: complete Freund’s adjuvant; OVA: ovalbumin. 
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CTB may also be introduced into DNA vaccines. For example, it has been shown that CTB fused  
to ovalbumin formulated as DNA vaccine leads to a strong anti-OVA T cell response when combined 
with a recombinant vaccinia boost regimen [51], and salivary IgA levels directed against the 
Streptococcus mutans wall associated protein A increased when a CTB encoding plasmid was coinjected 
with the protein A coding plasmid [63]. CTB may also be coadministered together with DNA vaccines 
that do not code themselves for CTB [54]. CTB activates murine bone marrow derived dendritic cells 
and macrophages cells via Toll-like receptor signaling pathways, leading to the expression of chemokines, 
mainly Th2 (IL-4, IL-10) but also Th1 cytokines (IFN-), and inflammatory cytokines (IL-1) in vitro 
and in vivo [53,59]. The generation of Th2 versus Th1 cytokines is independent from the route of 
immunization or the Ag as in several studies using one route and one Ag both types of cytokines were 
observed simultaneously [17,59]. When CTB and a DNA vaccine encoding for HIV Env were coinjected 
intramuscularly into mice, the response generated against Env was enhanced 10-fold, approximately, 
compared to the DNA vaccine administered alone [54]. It is possible, however, that some of these 
observations were due to contamination with LPS as a different report found that CTB can imprint 
dendritic cells to promote IgA production by B cells in vitro only in presence of LPS [64]. Direct 
interaction between CTB and TLR4 has nevertheless been show via ELISA [65]. 
As mentioned above, CTB has been used as adjuvant without being physically linked to the Ag.  
In the ovalbumin (OVA) asthma model, induced by aerosol formulation of the Ag and administration 
via the airway, CTB combined with OVA led to the suppression of airway eosinophilia, bronchial 
hyperreactivity and secretion of Th2 cytokines, i.e., IL-4, IL-10 and IL-5 that were reduced 2–5 fold, 
while IFN- was two-fold upregulated. Ag-specific IgA concentration in the lung was more than 10-fold 
incremented in comparison to administration of OVA alone [49]. Unfused CTB has also been combined 
with HIV recombinant gp160 and proteosomes [52] where it led to a 20- and 60-fold increase of serum 
and intestinal IgA, respectively. Hemagglutinin, formulated as a fusion protein with the major 
immunodominant region of the hepatitis B virus core protein (HBc) increased the survival rate of 
BALB/c mice challenged with Influenza virus by 50% when administered together with instead of 
without CTB [55]. CBT as unfused adjuvant was further used successfully in prevention infection 
against amoeba Naegleria fowleri (see below). Nevertheless, coadministration of CTB with the Ag 
without coupling the proteins is not always successful. In a detailed study the authors compared the 
immunogenic effect of the Plasmodium vivax ookinete surface protein Pvs25, injected subcutaneously 
either alone, coinjected with CTB, or coupled chemically to CTB, with or without incomplete Freund’s 
adjuvant (IFA), or with or without CT as additional adjuvant. Ab titers were indistinguishable when 
either Ag alone or Ag mixed with CTB was injected. Coupling to CTB augmented titers 16-fold. Ab 
titers of free Ag plus IFA versus free Ag incremented 19-fold, thus IFA and CTB were approximately 
comparable in terms of adjuvant efficacy. When IFA was combined with CTB-conjugated Ag, the titers 
incremented another 10-fold. The addition of CT to these three Ag formulations was analyzed via 
intranasal immunization. CT had a considerable effect (>10-fold increase of Ab titers) when combined 
with CTB-conjugated Ag, but no effect when combined with Ag alone or Ag plus CTB [60]. This study 
shows an advantage of conjugated Ag-CTB formulations, i.e., the possibility to combine it with another 
adjuvant leading to its further potentiation. When OVA was either injected as mixture with CTB or 
conjugated to CTB, the conjugated version elicited a 10-fold stronger Ab response [48]. As mentioned 
above, CTB can lead to activation of APCs and to the secretion of chemokines, thereby enhancing 
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immune responses. This could explain why CTB administered in an uncoupled form augments the 
immune response in some cases, although the latter two mentioned studies argue that coupling of CTB 
to the Ag is more efficient. 
6. CTB as Vaccine Adjuvant in Infectious Diseases 
As mentioned above, the presence of GM1 on the gut epithelium facilitates the entry of CTB  
into the body and the access to the immunological system. CTB has been used for two apparently 
contradictory goals, to improve protective immunity against infectious diseases and to reduce undesired 
autoimmune reactions.  
As for protective immunity against infections, oral coadministration of CTB with recombinant Nfa1 
protected mice against infection with the amoeba Naegleria fowleri, that can exist as a virulent pathogen 
causing amebic meningoencephalitis in humans and experimental animal models [59]. Nfa1 is a protein 
localized in the pseudopodia of the pathogen, and antibodies against this protein have been reported to 
reduce its pathogenicity [66]. In the study, IgG as well as IgA titers increased when CTB was added as 
adjuvant, leading to a 60% survival rate compared to 0% of animals immunized with Nfa1 only [59].  
An enhanced Ab response to the HIV Env protein encoded by a DNA vaccine when coadministered with 
CTB was already mentioned above [54]. Similarly, an elevated CD8 response was observed in mice 
immunized with a DNA vaccine coding for HIV gp120 when coadministered nasally/mucosally together 
with CTB and plasmid-encoded IL-12 [53]. As mentioned above, CTB coupled to merozoite surface 
protein-1 (MSP1-19) enhances the protection of mice against Plasmodium yoelii infection, a murine 
malaria model system, when administered either intranasally or subcutaneously, leading to increased 
serum IgG titers [20]. In a murine gastritis model a multiple epitope vaccine (CTB-UE) directed against 
Heliobacter pylori reduced IL-17 in the plasma, which went in parallel with a reduction of the pathogen 
burden in the stomach [67]. Off note, CTB immunization, independently of the route of administration 
(intranasally, i.p. or subcutaneously), can lead to protection in the suckling offspring as has been shown 
in mice [58]. 
7. CTB in Immune Suppression 
CTB has been analyzed for its capacity to induce immune suppression against allergic reactions and 
autoimmune disorders. Allergen epitopes have been successfully expressed as fusion proteins with CTB, 
such as Japanese Cedar pollen-derived T cell epitopes (Cry J 1 and Cry J 2 antigen) [25]. An experimental 
allergic rhinitis setup based on OVA as model antigen was used to analyze the effect and mechanism of 
CTB coadministration. CTB reduced several symptoms including TH2 cytokines, airway eosinophilia, 
and bronchial hyperreactivity. Mechanistically, CTB interfered with the capacity of dendritic cells to 
generate a TH2 response, increased their capacity to generate Foxp3+ Treg that, however, were not able 
to confer protection, and led to the production of IgA. Consequently, protection was obtained by the 
transfer of B cells from CTB treated animals [49]. A recent in vitro study using human dendritic cells 
(DC) has analyzed the mechanism further by which CTB in combination with autoantigen might 
contribute to active immune suppression. Co-culture of CTB fused to the autoantigen insulin with DCs, 
but neither insulin alone nor CTB alone induced up-regulation of the tryptophan catabolic enzyme 
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indoleamine 2,3-dioxygenase (IDO1) that has been shown to have immunosuppressive function [61]. IDO1 
expression was linked to NF-kB signaling as its blockage downregulated its production.  
B cells have been shown to play an important role in CTB-mediated sublingual tolerance induction. 
In B cell deficient mice, the induction of Treg was reduced compared to wild type animals. This could 
be corrected by adoptive B cell transfer prior to tolerance induction. However, B cell-sufficient as well 
as B cell-deficient mice treated sublingually with CTB-OVA suppressed an anti-OVA response after 
parenteral challenge with the Ag. It was shown that in B cell deficient mice, Foxp3-CD4+ T cell 
expressing TGF- increased strongly [68], leading the authors to speculate about two parallel pathways 
leading to oral tolerance induction, one being dependent on B cells but not the other. B cell-dependent 
oral tolerance was further found to necessitate expression of FcRIII by these cells [69]. An alternative 
approach implicating B cells to induce tolerance has been their in vitro incubation with CTB-coupled 
Ag and their subsequent transfer to mice. This led to TGF- and IL-10 expression by these cells in vivo 
and subsequently to the generation Foxp3+ regulatory cells. This was tested successfully using either 
OVA as model antigen or myelin oligodendrocyte glycoprotein peptide 35–55, the latter of which could 
be shown to prevent experimental autoimmune encephalomyelitis in this format [50].  
In type 1 diabetes, CTB has been used as adjuvant to prevent diabetes in a relevant mouse model, the 
autoimmunity prone non-obese diabetic (NOD) mouse. Most of these reports, using CTB as a fusion 
protein, in a conjugated or unconjugated form or included in recombinant vaccinia viruses, in combination 
with a variety of autoantigens relevant to this disease such as insulin or glutamic acid decarboxylase, 
have advertised success in disease prevention [70,71], claiming the induction of regulatory T cells or a 
Th2 response. However, we recently came to a different conclusion by employing a MHC-tetramer CD4 
T cell tracing approach in NOD mice. Using disease-relevant peptides fused to CTB and administrated 
orally we showed that in NOD mice Ag-specific CD4 T cells were not tolerized, but rather activated 
after parenteral challenge with the peptides, despite the generation of Ag-specific Foxp3+ CD4 T cells. 
Likewise, diabetes was not prevented in our hands. However, in diabetes-resistant F1 mice generated by 
crossing diabetes prone NOD mice with disease-resistant C57BL/6 mice, oral tolerance, i.e., the inability 
of Ag-specific T cells to proliferate in vivo after parenteral immunization, was restored using the  
above-mentioned prime-boost regimen [17]. These results show that when analyzing oral tolerance 
induction by CTB to treat autoimmune diseases, a background truly prone to autoimmunity such as the 
NOD mouse is needed in order to gain meaningful insights. This is easier to achieve in the case of type 
1 diabetes than in diseases currently needing induced model systems such as EAE. 
Since CTB can prevent infection but also autoimmune reactions, the question is how these two 
apparently opposite immune reactions can be achieved by the same adjuvant. As we have mentioned, 
CTB can induce Th1 and Th2 cytokines, thus leading to the generation of neutralizing Abs helpful in 
the protection against infectious diseases and activating protective T cell responses. When using CTB to 
prevent autoimmune diseases, the balance between Th1 and Th2 cytokines will likely decide whether 
the response will be protective rather than deleterious. Since in this scenario autoantigens are employed, 
this seems to generally favor Th2 responses and regulatory T cell generation or activation.  
  
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8. Conclusions 
The lack of toxicity combined with the stability and relative ease to express CTB either by its own or 
fused to peptides or proteins has made CTB an adjuvant easy to handle. The possibility to express the 
protein in a large variety of organisms further broadens its application potential. Its capacity to reduce 
antigen amounts up to 100-fold for immunization, due to its efficient binding to APCs and epithelium 
surfaces should make CTB a cost-effective adjuvant. To what extent it will serve to indeed prevent or 
reverse autoimmune diseases in humans remains an open question and a further challenge. However, 
our growing understanding of the immune system is likely to pave further roads in the future in order to 
modulate immune responses in the desired direction, be it immunostimulatory or immunomodulatory. 
CTB is currently being used in vaccines such as Dukoral, an anti-V. cholerae vaccine consisting of killed 
V. cholerae and recombinant CTB. CTB as adjuvant for human vaccines has been approved in Europe 
and Canada. Given the superb adjuvant effect of CTB it is likely that this protein should play an 
important role in the formulation of vaccines in the future. 
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